Arthur D. Little appoints Ulrica Sehlstedt to lead Global Healthcare & Life Sciences Practice
29.10.2019 12:38:00 EET | Business Wire | Press release
Arthur D. Little (ADL) today announced the appointment of Dr. Ulrica Sehlstedt as the new Global Practice Leader for its Global Healthcare & Life Sciences (HCLS) Practice.
With over 20 years of experience in the healthcare and life sciences sectors, Ulrica is a Partner based in ADL’s Stockholm office. She joined the company 13 years ago and has worked extensively for ADL clients across the healthcare and life sciences ecosystem; covering global industry players (pharma, medtech and biotech companies), healthcare providers (public and private), early stage life sciences companies and investors in the sector. Prior to joining ADL, she was CEO of a biotech start-up in molecular diagnostics and also has an extensive background in academic research.
ADL’s Global HCLS Practice works side-by-side with its clients to meet their challenges as the sector goes through an era of enormous medical and technological innovation, while delivering results in a more resource-constrained ecosystem. It achieves this through deep industry knowledge, combined with creative thinking. This enables ADL to work with its clients in harnessing innovation to overcome their most difficult strategic challenges.
Ulrica will take over from Nils Bohlin, who has successfully led the Global HCLS Practice for 8 years, nearly quadrupling its size. After a successful career of 37 years with ADL, Nils has reached retirement age, but will stay in close contact with the company in a new role as Senior Advisor.
Ignacio García Alves, Chairman and Chief Executive Officer at Arthur D. Little comments: “The healthcare and life sciences ecosystem is changing rapidly as innovation and digitalization radically disrupt the sector. At ADL we have already built a strong position in the market, and Ulrica’s leadership will drive further growth in the Global Healthcare & Life Sciences Practice, thanks to her wide experience, deep understanding and commitment to innovation.”
Dr. Ulrica Sehlstedt, Global Practice Leader, Global Healthcare & Life Sciences Practice at Arthur D. Little adds: “While innovation has always been central to healthcare, we are seeing unprecedented change as advances accelerate across the sector. At the same time available resources have not kept pace, meaning that balancing innovation and outcomes requires strategic understanding and market knowledge. ADL’s Global Healthcare and Life Sciences Practice is already perfectly positioned to help our clients meet these challenges, and I look forward to leading the team as the industry transforms.”
Ulrica holds a PhD in biophysics from Stockholm University, as well as an MSc in Chemical Engineering from Chalmers University of Technology, Gothenburg, Sweden. She has also been a member of the Swedish Research Council’s Scientific Council for Medicine for six years, and is regularly engaged in expert roles for life science research and industry initiatives directed towards governments and policy makers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005489/en/
Contact information
Cate Bonthuys
Catalyst Comms
+44 7746 56773
cate@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carta Rearchitects Private Capital Operations with Plugins for Claude29.7.2026 17:01:00 EEST | Press release
Carta, the connected platform and AI-native ecosystem for private capital, today announces broad availability of its suite of Plugins for Claude following the initial launch in April 2026. With more than 1,500 companies and firms already using the plugins, Carta is changing the way private capital teams — from founders to CFOs — fundamentally operate, bringing fund administration, cap table management, and dealflow analytics directly into the spreadsheets, presentations, and workflows they already use every day. "For the last decade, private capital operation teams have been held back by a hidden tax: the constant, manual handoff of data between disconnected systems," said Henry Ward, Carta CEO. "Carta is eliminating that broken loop entirely by embedding intelligence directly into the tools teams already use. We are not waiting for an AI-native future for private capital — it is running on Carta today." Carta didn't just give Claude a pipe to its data. Carta built its private-capital
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System29.7.2026 16:00:00 EEST | Press release
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNova™ system. The randomized controlled study will compare TriNova head-to-head with the commercially available Edwards EVOQUE™ TTVR system. The TRIVITA trial (NCT07516444) initiation marks a significant milestone in advancing treatment for tricuspid regurgitation (TR). The prospective, global, multicenter, randomized (1:1) controlled study is designed to evaluate the safety and effectiveness of the TriNova TTVR system in patients with severe or greater tricuspid regurgitation who are suitable for valve replacement. The study will be conducted in the US and Europe with up to 70 sites participating. The first patient was enrolled at the Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, and tre
Grid Dynamics Accelerates Enterprise AI-Native Transformation With Workforce Certification and GAIN Platforms Rollout29.7.2026 16:00:00 EEST | Press release
Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a leading provider of technology consulting, platform and product engineering, and AI-driven digital transformation services, today announced significant momentum in the adoption of its enterprise agentic AI solutions. Organizations across retail, financial services, manufacturing, CPG, and logistics industries are increasingly deploying Grid Dynamics’ agentic AI-native platforms and Forward Deployed Engineering (FDE)-led services to accelerate software delivery, improve operational efficiency, and transform business processes at scale. Grid Dynamics is widely recognized for its enterprise AI expertise and delivery capabilities across Fortune 1000 organizations. Grid Dynamics has partnership agreements with Anthropic and OpenAI to accelerate the adoption of these platforms within enterprises. By the end of October 2026, Grid Dynamics plans to have 90% of its engineers trained and certified on these platforms. Built to suppo
VDyne Announces First Patient Treated in TRIVITA US IDE Pivotal Study of the TriNova™ Transcatheter Tricuspid Valve Replacement System29.7.2026 16:00:00 EEST | Press release
VDyne Inc. (“VDyne”), a privately held medical device company developing an innovative transcatheter tricuspid valve replacement (TTVR) system, today announced that the first patient has been enrolled and treated in the TRIVITA US IDE pivotal study of the TriNova™ system. The randomized controlled study will compare TriNova head-to-head with the commercially available Edwards EVOQUE™ TTVR system. The TRIVITA trial (NCT07516444) initiation marks a significant milestone in advancing treatment for tricuspid regurgitation (TR). The prospective, global, multicenter, randomized (1:1) controlled study is designed to evaluate the safety and effectiveness of the TriNova TTVR system in patients with severe or greater tricuspid regurgitation who are suitable for valve replacement. The study will be conducted in the US and Europe with up to 70 sites participating. The first patient was enrolled at the Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, and tre
Experian Recognized by Chartis Research for Advancing AI Model Governance in Quantitative Analytics50 202629.7.2026 16:00:00 EEST | Press release
Experian today announced it has been recognized by Chartis Research as the winner in the Model Risk Management Environment category in the Quantitative Analytics50 2026 report. The recognition marks Experian's first appearance in the prestigious ranking and reinforces the company's position as a leading provider of data and AI-driven analytics solutions for regulated financial services organizations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729058148/en/ Chartis Research recognized Experian as the category winner for Model Risk Management Environment in the Quantitative Analytics50 2026 report. "This recognition from Chartis reflects the growing importance of governing AI with the same rigor used to build it," said Vijay Mehta, Chief AI Officer at Experian. "Financial institutions need to scale AI without sacrificing transparency, accountability or regulatory compliance. Our vision is to provide an integrated agenti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom